Stephen Calderwood, MD
Stephen Calderwood, MD
About Stephen Calderwood, MD
Clinical Interests:
- Bacterial gastroenteritis
- Endocarditis
- Meningitis
- Infectious diseases
Treats:
- Adult
Locations
Infectious Disease Associates
55 Fruit Street
Boston, MA 02114-2696
617-726-3811
617-724-7512
Fax: 617-726-7416
Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Infectious Disease, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Maine
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
My laboratory has ongoing collaborations with the International Centre for Diarrhoeal Disease Research in Dhaka, Bangladesh, to analyze human mucosal immune responses following natural V. cholerae infection, to analyze gene expression in V. cholerae directly in human samples, to use human immune responses following cholera to identify bacterial genes uniquely expressed during human infection, and to use this information to develop an improved cholera vaccine.